Benitec Biopharma Inc. BNTC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-07-11
Benitec Biopharma Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating margin | — | — | -25441.3% | -24457.5% | -23044.1% | -8118.6% | 21.2% |
| Net margin | — | — | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% |
| FCF margin | — | — | -24017.3% | -21797.3% | -22123.7% | -7480.4% | 36.0% |
| Return on assets | -38.1% | -41.7% | -438.2% | -304.8% | -64.9% | -71.4% | 13.6% |
| Return on equity | -39.0% | -46.0% | -9684.2% | -631.8% | -69.4% | -80.8% | 15.7% |
| Current ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 |
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.